Rocket


Overview
Financials
News + Filings





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Appointed director
CC transcript

Synaptogenix, Inc. Create: Alert

All | News | Filings
Date FiledTypeDescription
5:00 PM 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "Form of Series E Warrant",
"Form of Series F Warrant",
"Form of Pre-Funded Warrant",
"Form of Broker Warrant",
"Securities Purchase Agreement, by and among Synaptogenix, Inc. and the Buyers signatory thereto",
"Registration Rights Agreement, by and among Synaptogenix, Inc. and the Buyers signatory thereto",
"Engagement Letter, by and between Synaptogenix, Inc. and Katalyst Securities LLC",
"Placement Agency Agreement, by and between Synaptogenix, Inc., and GP Nurmenkari Inc",
"Synaptogenix Announces $14.0 Million Private Placement · Fully Funds Phase 2 Alzheimer’ s Disease Trial Being Conducted in Partnership with The National Institutes of Health · Provides Pathway for Strategic Partnerships on Other Indications NEW YORK, January 21, 2021 /PRNewswire/ -- Synaptogenix, Inc. , formerly Neurotrope Bioscience, Inc., announced today that it has entered into definitive securities purchase agreements with accredited investors to raise approximately $14.0 million in a private placement of common stock and warrants exercisable for common stock. In the private placement, the Company has agreed to sell shares of its common stock at a purchase price of $1.50 per share, one-year warrants to purchase an equal number of the Company’ s shares of common stock at a..."
01/19/2021 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Amendments to Articles of I...
Docs: "Corporation”), hereby certifies that on January 13, 2021, the Board of Directors of the Corporation (the “Board of Directors",
"RIGHTS AGREEMENT"
12/23/2020 10-Q Quarterly Report for the period ended September 30, 2020
12/16/2020 8-K Conference call transcript
Docs: "Script of Synaptogenix, Inc. conference call held on December 15, 2020"
12/10/2020 8-K Appointed a new director
Docs: "Amended and Restated Articles of Incorporation of Synaptogenix, Inc.",
"Bylaws of Synaptogenix, Inc",
"Separation and Distribution Agreement, by and between Neurotrope, Inc. and Synaptogenix, Inc",
"Tax Matters Agreement, by and between Neurotrope, Inc. and Synaptogenix, Inc",
"SEPARATION AGREEMENT",
"Dr. Alan J. Tuchman",
"SYNAPTOGENIX, INC. 2020 EQUITY INCENTIVE PLAN 1. DEFINITIONS.",
"STOCK OPTION AGREEMENT - INCORPORATED TERMS AND CONDITIONS",
"Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the Phase 2 study and further studies, and continued development of use of Bryostatin-1 for Alzheimer's disease and other cognitive diseases. Such forward-looking statements are subject to risks and uncertainties and other influences, many of which the Company has no control over. There can be no assurance that the clinical program for Bryostatin-1 will be successful in demonstrating safety and/or efficacy, that we will not encounter problems or delays in clinical development, or that Bryostatin-1 will ever receive regulatory approval or be successfully commercialized. Actual ..."
11/20/2020 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
11/12/2020 424B1 Form 424B1 - Prospectus [Rule 424(b)(1)]:
11/10/2020 EFFECT Form EFFECT - Notice of Effectiveness:
11/05/2020 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
10/09/2020 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
09/05/2013 D Form D - Notice of Exempt Offering of Securities
03/13/2013 D Form D - Notice of Exempt Offering of Securities

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy